Advertisement

Brain Tumor Pathology

, Volume 36, Issue 1, pp 14–19 | Cite as

Identification of a novel KLC1–ROS1 fusion in a case of pediatric low-grade localized glioma

  • Yoshiko NakanoEmail author
  • Arata Tomiyama
  • Takashi Kohno
  • Akihiko Yoshida
  • Kai Yamasaki
  • Tatsuya Ozawa
  • Kohei Fukuoka
  • Hiroko Fukushima
  • Takeshi Inoue
  • Junichi Hara
  • Hiroaki Sakamoto
  • Koichi Ichimura
Case Report

Abstract

The proto-oncogene tyrosine-protein kinase ROS1 (ROS1) is a tyrosine kinase that is closely related to anaplastic lymphoma kinase receptor (ALK). We describe a novel KLC1–ROS1 fusion identified in a case of pediatric low-grade glioma. This was detected by RNA sequencing and confirmed by reverse-transcription PCR and fluorescent in situ hybridization. Immunohistochemical staining for ROS1 was positive in the tumor cytoplasm. In vitro analysis demonstrated the oncogenic activity of this fusion, which was suppressed by the ALK/ROS1 inhibitor, crizotinib. Our case and others suggest that various ROS1 fusions might be present in a subset of pediatric gliomas, which could be targeted for therapy.

Keywords

Crizotinib Immunohistochemistry FISH KLC1–ROS1 fusion Pediatric glioma 

Notes

Acknowledgements

The authors thank the patient and their family for participating in this research. We thank T. Ushijima, S. Yamashita, and R. Nagano for their advice and technical support for DNA analysis. This work was supported in part by the Practical Research for Innovative Cancer Control from Japan Agency for Medical Research and Development, AMED [no. JP17ck0106168 (T.K. and K. I.)].

Compliance with ethical standards

Conflict of interest

The authors declare no conflicts of interest associated with this manuscript.

Supplementary material

10014_2018_330_MOESM1_ESM.doc (49 kb)
Supplementary material 1 (DOC 49 KB)
10014_2018_330_MOESM2_ESM.doc (44 kb)
Supplementary material 1 (DOC 45 KB)

References

  1. 1.
    Davies KD, Doebele RC (2013) Molecular pathways: ROS1 fusion proteins in cancer. Clin Cancer Res 19:4040–4045CrossRefGoogle Scholar
  2. 2.
    Uguen A, De Braekeleer M (2016) ROS1 fusions in cancer: a review. Future Oncol 12:1911–1928CrossRefGoogle Scholar
  3. 3.
    Lim SM, Choi J, Chang JH et al (2015) Lack of ROS1 gene rearrangement in glioblastoma multiforme. PLoS One 10:e0137678CrossRefGoogle Scholar
  4. 4.
    Verhey KJ, Hammond JW (2009) Traffic control: regulation of kinesin motors. Nat Rev Mol Cell Biol 10:765–777CrossRefGoogle Scholar
  5. 5.
    Togashi Y, Soda M, Sakata S et al (2012) KLC1-ALK: a novel fusion in lung cancer identified using a formalin-fixed paraffin-embedded tissue only. PLoS One 7:e31323CrossRefGoogle Scholar
  6. 6.
    Wang P, Xiao P, Ye Y et al (2017) Rapid response of brain metastasis to crizotinib in a patient with KLC1-ALK fusion and MET gene amplification positive non-small cell lung cancer: a case report. Cancer Biol Med 14:183–186CrossRefGoogle Scholar
  7. 7.
    Johnson A, Severson E, Gay L et al (2017) Comprehensive genomic profiling of 282 pediatric low- and high-grade gliomas reveals genomic drivers, tumor mutational burden, and hypermutation signatures. Oncologist 22:1478–1490CrossRefGoogle Scholar
  8. 8.
    Coccé MC, Mardin BR, Bens S et al (2016) Identification of ZCCHC8 as fusion partner of ROS1 in a case of congenital glioblastoma multiforme with a t(6;12)(q21;q24.3). Genes Chromosomes Cancer 55:677–687CrossRefGoogle Scholar
  9. 9.
    Olsen TK, Panagopoulos I, Meling TR et al (2015) Fusion genes with ALK as recurrent partner in ependymoma-like gliomas: a new brain tumor entity? Neuro Oncol 17:1365–1373CrossRefGoogle Scholar
  10. 10.
    Aghajan Y, Levy ML, Malicki DM et al (2016) Novel PPP1CB-ALK fusion protein in a high-grade glioma of infancy. BMJ Case Rep.  https://doi.org/10.1136/bcr-2016-217189 Google Scholar
  11. 11.
    Kiehna EN, Arnush MR, Tamrazi B et al (2017) Novel GOPC(FIG)-ROS1 fusion in a pediatric high-grade glioma survivor. J Neurosurg Pediatr 20:51–55CrossRefGoogle Scholar
  12. 12.
    Rossing M, Yde CW, Sehested A et al (2017) Genomic diagnostics leading to the identification of a TFG-ROS1 fusion in a child with possible atypical meningioma. Cancer Genet 212–213:32–37CrossRefGoogle Scholar
  13. 13.
    Cameron L, Solomon B (2015) New treatment options for ALK-rearranged non-small cell lung cancer. Curr Treat Options Oncol 16:49CrossRefGoogle Scholar
  14. 14.
    Bubendorf L, Büttner R, Al-Dayel F et al (2016) Testing for ROS1 in non-small cell lung cancer: a review with recommendations. Virchows Arch 469:489–503CrossRefGoogle Scholar
  15. 15.
    Yoshida A, Tsuta K, Wakai S et al (2014) Immunohistochemical detection of ROS1 is useful for identifying ROS1 rearrangements in lung cancers. Mod Pathol 27:711–720CrossRefGoogle Scholar
  16. 16.
    Fujita H, Yoshida A, Taniguchi H et al (2015) Adult-onset inflammatory  myofibroblastic tumour of the stomach with a TFG-ROS1 fusion. Histopathology 66:610–612CrossRefGoogle Scholar
  17. 17.
    Yamamoto H, Yoshida A, Taguchi K et al (2016) ALK, ROS1 and NTRK3 gene rearrangements in inflammatory myofibroblastic tumours. Histopathology 69:72–83CrossRefGoogle Scholar

Copyright information

© The Japan Society of Brain Tumor Pathology 2018

Authors and Affiliations

  • Yoshiko Nakano
    • 1
    • 2
    Email author
  • Arata Tomiyama
    • 1
    • 3
  • Takashi Kohno
    • 4
  • Akihiko Yoshida
    • 5
  • Kai Yamasaki
    • 1
    • 2
  • Tatsuya Ozawa
    • 1
  • Kohei Fukuoka
    • 1
  • Hiroko Fukushima
    • 6
  • Takeshi Inoue
    • 6
  • Junichi Hara
    • 2
  • Hiroaki Sakamoto
    • 7
  • Koichi Ichimura
    • 1
  1. 1.Division of Brain Tumor Translational ResearchNational Cancer Center Research InstituteTokyoJapan
  2. 2.Department of Pediatric Hematology/OncologyOsaka City General HospitalOsakaJapan
  3. 3.Department of NeurosurgeryNational Defense Medical CollegeSaitamaJapan
  4. 4.Division of Genome BiologyNational Cancer Center Research InstituteTokyoJapan
  5. 5.Department of Pathology and Clinical LaboratoriesNational Cancer Center HospitalTokyoJapan
  6. 6.Department of PathologyOsaka City General HospitalOsakaJapan
  7. 7.Department of Pediatric NeurosurgeryOsaka City General HospitalOsakaJapan

Personalised recommendations